longer subject to

Form 5 obligations may continue. See

Instruction 1(b).

Section 16. Form 4 or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response... 0.5

(Instr. 4)

\$5,000

Amount

Number

Shares

5,000

\$0(2)

(Instr. 4)

D

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Respons	es)					,							
Name and Address of Reporting Person MATHER CHARLES E IV				2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]			orp.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director			pelow)			
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 06/17/2014				below)						
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip))	Table I - Non-Derivative Securities Acqu				iired, Disposed of, or Beneficially Owned			i			
1.Title of S (Instr. 3)	, E	. Transaction Date Month/Day/Year)	Exect any	nth/Day/Year)	ransaction Code Instr. 8)	4. Securities Acquired (A) Disposed of ((Instr. 3, 4 an (A) or Amount (D)	D) d 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	d Direct (D)	7. Nat of Ind Benef Owne (Instr.	irect icial rship			
Reminder:		separate line for 6	ach cl	ass of securities	beneficially	owned								
					inf red	ormation co	ntain spond	nd to the collection ed in this form are lunless the form control number.	e not displays a		1474 9-02)			
				ative Securities outs, calls, warr	- '	• .		rities)						
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Ye	Ex ar) an	A. Deemed secution Date, if y Ionth/Day/Year)	4. Transactio Code (Instr. 8)		Expira	te Exercisable and ation Date th/Day/Year)	7. Title and Ar of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)

(Instr. 3, 4, and 5)

(A)

5,000

Code

A

Date

Exercisable Date

<u>(1)</u>

Expiration

06/17/2024

Title

Common

Stock

Reporting Owners

\$ 9.87

06/17/2014

Departing Owner Name / Address	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
MATHER CHARLES E IV C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022	X						

Signatures

Stock

Option

/s/ Charles Mather	06/20/2014
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- $\textbf{(1)} \ The \ option \ vests \ 1/3rd \ on \ the \ first \ anniversary \ of \ issuance \ and \ 1/36th \ each \ month \ thereafter \ for \ 24 \ months.$
- (2) The option was granted pursuant to the Issuer's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.